Publication details
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans
| Authors | |
|---|---|
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | BIODRUGS |
| Citation | |
| web | https://link.springer.com/article/10.1007/s40259-023-00593-7 |
| Doi | http://dx.doi.org/10.1007/s40259-023-00593-7 |
| Description | Background Biosimilars have been introduced with the goal of competing with high-priced biologic therapies, yet their adoption has been slower than expected and resulted in limited efficiency gains. We aimed to explore factors associated with biosimilar coverage relative to their reference products by commercial plans in the United States (US). |